STAT3 antagonist-1
STAT3 antagonist-1 is a selective STAT3 antagonist. STAT3 antagonist-1 induces Autophagy-associated cell death. STAT3 antagonist-1 inhibits cancer stemness and epithelial-mesenchymal transition. STAT3 antagonist-1 can be used for research on pancreatic cancer and colorectal cancer.
For research use only. We do not sell to patients.
- Formula: C16H18N2O4
- Molecular Weight:302.33
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
STAT3 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MIA PaCa-2 | GI50 |
34.4 μM
|
Growth inhibition against human MIA PaCa-2 pancreatic ductal adenocarcinoma cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay.
Growth inhibition against human MIA PaCa-2 pancreatic ductal adenocarcinoma cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay.
|
42551351 |
| MIA PaCa-2 | GI50 |
8.2 μM
|
Growth inhibition against human MIA PaCa-2 pancreatic ductal adenocarcinoma cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay.
Growth inhibition against human MIA PaCa-2 pancreatic ductal adenocarcinoma cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay.
|
42551351 |
| MIA PaCa-2 | GI50 |
0.85 μM
|
Growth inhibition against human MIA PaCa-2 pancreatic ductal adenocarcinoma cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay.
Growth inhibition against human MIA PaCa-2 pancreatic ductal adenocarcinoma cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay.
|
42551351 |
| HCT-116 | GI50 |
51.5 μM
|
Growth inhibition against human HCT 116 colorectal cancer cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay.
Growth inhibition against human HCT 116 colorectal cancer cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay.
|
42551351 |
| HCT-116 | GI50 |
20.5 μM
|
Growth inhibition against human HCT 116 colorectal cancer cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay.
Growth inhibition against human HCT 116 colorectal cancer cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay.
|
42551351 |
| HCT-116 | GI50 |
4.4 μM
|
Growth inhibition against human HCT 116 colorectal cancer cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay.
Growth inhibition against human HCT 116 colorectal cancer cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay.
|
42551351 |
In Vitro
STAT3 antagonist-1 (Compound P42) (10-50 μM) selectively targets the STAT3 SH2 domain over the DNA-binding domain, as demonstrated by potent inhibition in the STAT3127-688:phosphopeptide FP assay (85% at 10 μM) with a selectivity ratio of 5.00[1].
STAT3 antagonist-1 (24-72 h) exhibits potent growth inhibition in KRAS-mutant MIA PaCa-2 (GI50 ~0.85 μM at 72 h) and HCT 116 (GI50 ~4.4 μM at 72 h) cancer cell lines[1].
STAT3 antagonist-1 (10 μM; 72 h) exhibits selective cytotoxicity toward cancer cell lines at 10 μM, with the highest growth inhibition in MIA PaCa-2 (75%), DLD-1 (77%), and HCT 116 (62%), and minimal effect on non-cancerous MC3T3-E1 cells[1].
STAT3 antagonist-1 (0.1-10 μM; 24-48 h) inhibits STAT3 phosphorylation in MIA PaCa-2 and HCT 116 cells without affecting the total protein levels of upstream kinases JAK2 and SRC[1].
STAT3 antagonist-1 (0.3-30 μM; 24-48 h) induces autophagy-associated cell death in MIA PaCa-2 and HCT 116 cells[1].
STAT3 antagonist-1 (0.3-30 μM; 24-48 h) activates autophagy in MIA PaCa-2 and HCT 116 cells, characterized by increased LC3II/I ratios and decreased p62 levels[1].
STAT3 antagonist-1 (0.3-30 μM) abrogates cancer stemness potential in MIA PaCa-2 and HCT 116 cells by inhibiting colony formation[1].
STAT3 antagonist-1 (0.3-3 μM) down-regulates EMT/stemness markers SNAIL and ZEB1 in MIA PaCa-2 and HCT 116 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MIA PaCa-2, AsPC-1, DLD-1, HCT 116, and MC3T3-E1
-
Concentration:10 μM
-
Incubation Time:72 h
-
Result:Showed 75% growth inhibition in MIA PaCa-2, 62% in HCT 116, 77% in DLD-1, and 22% in AsPC-1.
In non-cancerous MC3T3-E1 cells, GI values were estimated to be >100 μM at 24 h, >100 μM at 48 h, and 30-100 μM at 72 h.
-
Cell Line:MIA PaCa-2 and HCT 116
-
Concentration:0.1, 1, and 10 μM
-
Incubation Time:24 h (MIA PaCa-2); 48 h (HCT 116)
-
Result:In MIA PaCa-2 cells, down-regulated p-STAT3 activity without affecting JAK2 and SRC.
Significantly abrogated p-STAT3 at as low as 1 μM.
Inhibited total STAT3 significantly at 10 μM.
In HCT 116 cells, inhibited STAT3 phosphorylation without affecting JAK2 and SRC.
-
Cell Line:MIA PaCa-2 and HCT 116
-
Concentration:0.3, 3, and 30 μM (MIA PaCa-2); 0.3 and 3 μM (HCT 116)
-
Incubation Time:24 h (MIA PaCa-2); 48 h (HCT 116)
-
Result:Induced significant autophagy at 0.3-30 μM in MIA PaCa-2 cells after 24 h.
Induced consistent autophagy at 0.3 and 3 μM in HCT 116 cells after 48 h.
Chemical Information
-
Molecular Weight 302.33
-
Formula C16H18N2O4
-
SMILES
OC1=C(OC)C=CC(/C=N/NC2=CC=C(OC)C(OC)=C2)=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Autophagy
Autophagy is a process in which eukaryotic cells use lysosomes to degrade their own cytoplasmic proteins and damaged organelles under the regulation of autophagy related gene (Atg). Microtubule-associated proteins light chain 3 (LC3) is recognized as autophagy marker, which transfers from cytoplasmic LC3 (LC3-I) to membrane type (LC3-II). LC3-II/I ratio could be detected by Western Blot and fluorescence microscopy.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
-
Macroautophagy Solutions
Macroautophagy is a conserved lysosome-dependent degradation pathway in which cytoplasmic material is sequestered into double-membrane autophagosomes and delivered to lysosomes for degradation and recycling. The pathway supports cellular homeostasis during nutrient limitation, organelle stress, protein-aggregate accumulation, infection, differentiation, and tissue remodeling by coupling cargo sequestration, autophagosome maturation, lysosomal fusion, and degradation of cargo-derived macromolecules. The core molecular sequence includes initiation by nutrient- and stress-regulated autophagy machinery, autophagosome nucleation, LC3/ATG8-family conjugation to autophagosomal membranes, cargo selection through receptors such as SQSTM1/p62, autophagosome-lysosome fusion, and lysosomal degradation. LC3 was identified as a mammalian homolog of yeast Atg8 that localizes to autophagosomal membranes after processing, and p62/SQSTM1 was shown to connect ubiquitinated cargo with autophagic degradati
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)